Managing Systemic Inflammation and the Symptoms of COVID-19
Disrupting the Binding of ACE2 to COVID-19 Spike Protein
Learn how our team of experts worked to determine if serum-derived bovine immunoglobulin (SBI) is able to bind to the SARS-CoV-2 RBD protein and disrupt RBD-ACE2 binding, preventing viral entry
Inhibiting Proteolysis of COVID-19
Read more about how our team of scientists were able to determine if serum-derived bovine immunoglobulin (SBI) is able to inhibit proteolytic cleavage of the SARS-CoV-2 spike protein S2’ domain by TMPRSS2.
EnteraGam® COVID-19 Clinical
Trial in Spain
Entera Health, in cooperation with Lemus Buhils, received IRB approval to conduct a clinical trial in Barcelona, Spain using EnteraGam® to manage inflammation and the symptoms associated with COVID-19 infections.